News | June 21, 2010

Renal Denervation Shows Durability of Blood Pressure Reduction

June 21, 2010 – Long-term data presented today from Ardian’s Symplicity HTN-1 study demonstrate that the significant reductions in blood pressure achieved using renal denervation (RDN) treatment are sustained through 24 months. The data were presented at the late-breaking trials session of the European Society of Hypertension (ESH) Annual Scientific meeting in Oslo, Norway.

The multicenter Symplicity HTN-1 study enrolled patients from Australia, the United States and Europe who had persistently elevated blood pressure despite treatment with an average of five medications. Dr. Markus Schlaich of the Baker Heart and Diabetes Institute in Melbourne, Australia, reported that the straightforward endovascular procedure safely produces a mean blood pressure reduction of -33/-15 mmHg at 24 months in the study cohort.

Both vascular and renal safety were also carefully assessed in the study and reported during the presentation. Renal vascular safety was assessed by imaging treated arteries both acutely and chronically for up to nine months. No evidence of treatment-related abnormalities or stenoses was reported. Kidney function was assessed with serial measures of serum creatinine and calculation of glomerular filtration rate (GFR). The mean GFR in the study cohort remained stable at latest follow-up.

“There is no question that we are having a positive impact on our patients in terms of hypertension, insulin resistance and other risk factors,” Schlaich said. “The results presented today suggest that these effects might be long-lasting.”

Based on pilot study results, Ardian Inc. initiated the Symplicity HTN-2 trial, a prospective, multicenter randomized study comparing patients receiving RDN treatment to those receiving rigorous medical therapy. The trial enrolled 106 patients and completed treatments in March 2010. An earlier presentation at the ESH meeting showed that treatment delivery was carried out with no major adverse events in all 52 patients randomized to treatment. Primary endpoint results are expected in the fourth quarter of 2010.

For more information:

Related Content

BioCardia Initiates Commercial Release of Avance Steerable Introducer
News | Catheters | October 23, 2019
BioCardia announced the U.S. commercial availability of its Avance Bi-Directional Steerable Introducer Sheath for...
Cook Medical Launches 2.6 Fr CXI Support Catheter
Technology | Catheters | August 23, 2019
August 23, 2019 — Cook Medical recently released the second generation of the 2.6 Fr CXI...
Biocardia Receives FDA Clearance for Avance Steerable Introducer Family
Technology | Catheters | May 16, 2019
BioCardia Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Avance steerable introducer...
Navitian Coronary Microcatheter Receives CE Mark Approval
News | Catheters | February 21, 2019
Navitian, the new coronary microcatheter from iVascular, recently received CE mark approval. The device was approved to...
First U.S. Patients Treated With OrbusNeich Teleport Microcatheter
News | Catheters | January 31, 2019
Cardiovascular Systems Inc. announced that the first patients in the United States were treated using the OrbusNeich...
Merit Medical Acquires Assets of Vascular Insights LLC
News | Catheters | December 18, 2018
Merit Medical Systems Inc. announced that it has acquired substantially all of the assets of Vascular Insights LLC,...
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters | October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters | August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Teleflex, FDA 510k clearance, TrapLiner Catheter, U.S. launch
Technology | Catheters | March 02, 2017
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
Merit Medical Systems, SwiftNINJA Steerable Microcatheter, FDA 510(k) clearance
Technology | Catheters | November 09, 2016
November 9, 2016 — Merit Medical Systems Inc.